Ascierto et al. [22] explored the gene expression landscape of PD-L1+RCCs derived from patients with divergent clinical outcomes after anti-PD-1 therapy and showed that a signature of up-regulated metabolic genes was associated with treatment failure in patients with PD-L1+RCC. The gene discussed is CD274; the disease is renal cell carcinoma.